A PIK3CA pyrosequencing-based assay that excludes pseudogene interference

Journal of Molecular Diagnostics

Volumn 14, Issue 1, 2012, Pages 56-60

  Baker, Christine L ^a   Vaughn, Cecily P ^a   Samowitz, Wade S ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER TISSUE; CHROMOSOME 22; CODON; COLORECTAL CANCER; DNA SEQUENCE; EXON; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PSEUDOGENE; PYROSEQUENCING; WILD TYPE;

BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PSEUDOGENES; RAS PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84555178784     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.08.004     Document Type: Article

References (20)

1. G. Ligresti, L. Militello, L.S. Steelman, A. Cavallaro, F. Basile, F. Nicoletti, F. Stivala, J.A. McCubrey, M. Libra PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches Cell Cycle 8 2009 1352 1358
2. M. Mohseni, B.H. Park PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001 J Clin Invest 120 2010 2655 2658
3. X. Pu, M.A. Hildebrandt, C. Lu, J. Lin, D.J. Stewart, Y. Ye, J. Gu, M.R. Spitz, X. Wu PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy Lung Cancer 71 2011 82 88
4. W. De Roock, B. Claes, D. Bernasconi, J. De Schutter, B. Biesmans, G. Fountzilas Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 2010 753 762
5. M.A. Aleskandarany, E.A. Rakha, M.A. Ahmed, D.G. Powe, E.C. Paish, R.D. Macmillan, I.O. Ellis, A.R. Green PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis Breast Cancer Res Treat 122 2010 45 53
6. S. Ogino, K. Nosho, G.J. Kirkner, K. Shima, N. Irahara, S. Kure, A.T. Chan, J.A. Engelman, P. Kraft, L.C. Cantley, E.L. Giovannucci, C.S. Fuchs PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer J Clin Oncol 27 2009 1477 1484
7. Y. He, L.J. Van't Veer, I. Mikolajewska-Hanclich, M.L. van Velthuysen, E.C. Zeestraten, I.D. Nagtegaal, C.J. van de Velde, C.A. Marijnen PIK3CA mutations predict local recurrences in rectal cancer patients Clin Cancer Res 15 2009 6956 6962
8. B.S. Jaiswal, V. Janakiraman, N.M. Kljavin, J. Eastham-Anderson, J.E. Cupp, Y. Liang, D.P. Davis, K.P. Hoeflich, S. Seshagiri Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors PLoS One 4 2009 e5717
9. L. Zhao, P.K. Vogt Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proc Natl Acad Sci U S A 105 2008 2652 2657 (Pubitemid 351520568)
10. C.I. Muller, C.W. Miller, W.K. Hofmann, M.E. Gross, C.S. Walsh, N. Kawamata, Q.T. Luong, H.P. Koeffler Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene Leuk Res 31 2007 27 32 (Pubitemid 44709746)
11. L.N. Spirio, W. Samowitz, J. Robertson, M. Robertson, R.W. Burt, M. Leppert, R. White Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps Nat Genet 20 1998 385 388 (Pubitemid 28541640)
12. K. Nosho, T. Kawasaki, M. Ohnishi, Y. Suemoto, G.J. Kirkner, D. Zepf, L. Yan, J.A. Longtine, C.S. Fuchs, S. Ogino PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations Neoplasia 10 2008 534 541 (Pubitemid 351770297)
13. R.E. Board, N.J. Thelwell, P.F. Ravetto, S. Little, M. Ranson, C. Dive, A. Hughes, D. Whitcombe Multiplexed assays for detection of mutations in PIK3CA Clin Chem 54 2008 757 760 (Pubitemid 351573719)
14. Z. Zhang, M. Gerstein Large-scale analysis of pseudogenes in the human genome Curr Opin Genet Dev 14 2004 328 335 (Pubitemid 38903122)
15. W. Qiu, F. Schonleben, X. Li, D.J. Ho, L.G. Close, S. Manolidis, B.P. Bennett, G.H. Su PIK3CA mutations in head and neck squamous cell carcinoma Clin Cancer Res 12 2006 1441 1446
16. S. Ogino, T. Kawasaki, M. Brahmandam, L. Yan, M. Cantor, C. Namgyal, M. Mino-Kenudson, G.Y. Lauwers, M. Loda, C.S. Fuchs Sensitive sequencing method for KRAS mutation detection by pyrosequencing J Mol Diagn 7 2005 413 421 (Pubitemid 41149657)
17. E. Lopez-Knowles, S. Hernandez, N. Malats, M. Kogevinas, J. Lloreta, A. Carrato, A. Tardon, C. Serra, F.X. Real PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors Cancer Res 66 2006 7401 7404 (Pubitemid 44289191)
18. Y. Samuels, L.A. Diaz Jr, O. Schmidt-Kittler, J.M. Cummins, L. Delong, I. Cheong, C. Rago, D.L. Huso, C. Lengauer, K.W. Kinzler, B. Vogelstein, V.E. Velculescu Mutant PIK3CA promotes cell growth and invasion of human cancer cells Cancer Cell 7 2005 561 573 (Pubitemid 40799249)
19. J. Abubaker, P.P. Bavi, S. Al-Harbi, A.K. Siraj, F. Al-Dayel, S. Uddin, K. Al-Kuraya PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma Leukemia 21 2007 2368 2370 (Pubitemid 350011714)
20. W. De Roock, D.J. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, S. Siena, S. Lamba, S. Arena, M. Frattini, H. Piessevaux, E. Van Cutsem, C.J. O'Callaghan, S. Khambata-Ford, J.R. Zalcberg, J. Simes, C.S. Karapetis, A. Bardelli, S. Tejpar Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 2010 1812 1820